WebDoctor Encyclopedia

Central nervous system Childhood

Desmoplastic infantile ganglioglioma and astrocytoma (DIG/DIA)

Desmoplastic infantile ganglioglioma and astrocytoma are rare low-grade brain tumours of babies. They are often very large with a big cyst but usually behave benignly, and surgery gives most children a very good outlook.

Medically reviewed Last reviewed October 21, 2026

What are desmoplastic infantile ganglioglioma and astrocytoma?

Desmoplastic infantile ganglioglioma (DIG) and desmoplastic infantile astrocytoma (DIA) are rare brain tumours of babies and very young children. They are usually very large when found, with a big fluid-filled cyst and a solid part that sits on the surface of the brain and sticks to its outer covering, the dura.

Despite their size and dramatic appearance on scans, these tumours are usually slow-growing and low-grade. The World Health Organization (WHO) classifies them together as a single tumour type, CNS WHO grade 1, the lowest grade (Wang et al., 2021). Most children do well after surgery.

The word desmoplastic means that the tumour contains a lot of tough, scar-like connective tissue. Ganglioglioma means the tumour contains both nerve cells (ganglion cells) and glial support cells. In astrocytoma, only glial cells (astrocytes) are seen. DIG is more common than DIA.

How it differs from ganglioglioma

Ordinary ganglioglioma, described on our page on ganglioglioma, is also a low-grade tumour made of nerve and glial cells. However, it usually affects older children and young adults and typically causes epilepsy.

Feature Ganglioglioma DIG/DIA
Typical age Older children, teenagers and young adults Babies, usually under two
Size at diagnosis Usually small Often very large
Cyst Sometimes Usually a large cyst
Dura Usually not attached Attached to the brain covering
First symptom Seizures Rapidly growing head, bulging soft spot
Scar-like tissue Limited Abundant
Grade CNS WHO grade 1 CNS WHO grade 1

1. Key facts at a glance

Feature Details
Type of tumour Low-grade glioneuronal or glial brain tumour
Grade CNS WHO grade 1
How common Very rare; a few hundred cases reported worldwide
Typical age Babies; median around 7 months in a pooled analysis
Sex Slightly more common in boys
Location Surface of the cerebral hemispheres, often frontal and parietal lobes
Main treatment Surgery
Other treatments Observation, chemotherapy or targeted drugs for regrowth
Outlook Usually very good

2. Types

Type Cells present Notes
DIG Astrocytes plus nerve (ganglion) cells About two-thirds of cases
DIA Astrocytes only About a quarter of cases
Non-infantile desmoplastic tumours Same features in older children or adults Rare

In an individual patient analysis of 188 published cases, about 68% were DIG and 25% were DIA. DIA was more often found in deep locations and was more often associated with spread along the brain coverings (Wang et al., 2021).

Molecular groups

Researchers now use DNA methylation profiling to classify brain tumours. DIG/DIA has its own methylation group. Gene changes in the MAPK pathway, especially BRAF mutations, are found in a subset, roughly one in three cases (Lampros et al., 2025).

3. Causes and risk factors

The cause is not known. These tumours appear to begin during brain development before or shortly after birth.

Factor Notes
Age Almost all cases occur in the first two years of life
Sex Slight male predominance
BRAF and other MAPK gene changes Present in the tumour in some children
Inherited conditions None known
Pregnancy factors No known link with anything the parents did

Parents often ask whether something during pregnancy caused the tumour. There is no evidence that diet, medicines, infections or other exposures during pregnancy play a role.

4. How does it look

On scans

Scan Typical findings
Cranial ultrasound Through the soft spot in babies; may first show a large mass or cyst
CT Very large cyst with a solid part near the surface; may show pressure on the brain
MRI Large cyst with a solid nodule that enhances strongly with contrast and is attached to the dura
Spine MRI Looks for spread along the spinal coverings

Typical MRI features include a large, mixed solid and cystic mass with a solid part that lights up brightly with contrast (Bianchi et al., 2016). In an Italian series, tumours averaged more than 200 cm3 in volume, which is very large for a baby’s head (Imperato et al., 2021).

Under the microscope

Feature Description
Desmoplastic stroma Dense connective tissue rich in reticulin fibres
Astrocytes Elongated glial cells, positive for GFAP
Ganglion cells Present in DIG; positive for neuronal markers such as synaptophysin
Primitive cells Small immature cells may be present and can look worrying
Ki-67 index Usually low

The small primitive cells can resemble a high-grade tumour. Pathologists know this pattern and do not take it as a sign of malignancy on its own (Bianchi et al., 2016).

5. Symptoms

Babies’ skull bones are not yet fused, so the head can expand as a tumour grows. This often allows the tumour to become very large before symptoms appear.

Common symptoms

  • Rapid growth of the head (increasing head circumference)
  • A tense or bulging soft spot (fontanelle)
  • Vomiting and irritability
  • Sleepiness or reduced feeding
  • Seizures

Less common symptoms

Symptom Possible cause
Eyes looking downwards (“setting sun” sign) Raised pressure in the head
Weakness of one side of the body Pressure on movement areas
Delayed development Long-standing pressure or seizures
Prominent scalp veins Raised pressure

A review of 222 patients found that hydrocephalus, a build-up of fluid in the head, was the most common first sign in babies, while seizures were more common in older children (Lampros et al., 2025).

When to seek medical advice

Take your baby to a doctor urgently if the head is growing quickly, the soft spot is bulging, or your baby is vomiting repeatedly, unusually sleepy or has a seizure.

6. Diagnosis

Step What is done
Examination Head size measurement, fontanelle check, neurological assessment
Ultrasound Quick first test in young babies
MRI of the brain and spine Main imaging test, often under sedation or general anaesthetic
Blood tests Blood count and clotting before surgery
Surgery Provides tissue for diagnosis and removes the tumour
Molecular testing BRAF and methylation profiling

Why surgery comes first

In most brain tumours, doctors try to confirm the diagnosis with a biopsy before planning treatment. With DIG/DIA, the tumour is usually so large and causes so much pressure that an operation is needed straight away. The surgery both relieves the pressure and provides tissue for diagnosis.

7. Treatment

Treatment takes place at a children’s neurosurgical centre with a paediatric neuro-oncology team.

Surgery

Aspect Details
Aim Remove as much tumour as safely possible
Cyst drainage The large cyst is drained during surgery
Challenges Very large, vascular tumours in small babies with little blood volume
Staged operations Sometimes needed for very large tumours
Hydrocephalus treatment A shunt may be needed in some children

Complete removal is the goal, but it is often difficult. The literature shows total removal in roughly a third to just over half of children (Bianchi et al., 2016; Lampros et al., 2025). Blood loss during surgery is a real risk in tiny babies, and one baby in the Italian series died from it soon after the operation (Imperato et al., 2021).

After partial removal

Situation Usual approach
Stable remaining tumour Regular MRI monitoring
Growth of remaining tumour Repeat surgery is often the first option
Tumour that cannot be removed Chemotherapy
BRAF-mutated tumour BRAF and MEK inhibitors may be considered

Remaining tumour often stays stable or even shrinks. In the Italian series, more than half the children needed more than one operation, yet most were alive and well at last follow-up (Imperato et al., 2021).

Chemotherapy and targeted drugs

Treatment Notes
Carboplatin and vincristine Common first choice when drug treatment is needed
Other low-grade glioma regimens Used for progression
BRAF and MEK inhibitors Options for tumours with BRAF changes

Radiotherapy

Radiotherapy is avoided in young children because of serious long-term effects on the developing brain. Experts consider it to have no routine role in DIG/DIA (Imperato et al., 2021).

Side effects

Treatment Possible side effects
Surgery Bleeding, infection, seizures, weakness, need for a shunt
Shunt Blockage or infection needing further surgery
Carboplatin and vincristine Low blood counts, infection, allergic reactions, constipation, nerve effects
BRAF and MEK inhibitors Skin rash, fever, tiredness, eye or heart effects

8. Outlook (prognosis)

The outlook is usually very good. In a review of 222 patients, recurrence occurred in about 6% and spread in about 2%, and long-term survival was high (Lampros et al., 2025).

Factor Effect
Complete removal Linked to better survival in a pooled analysis
Spread along the brain coverings at diagnosis Linked to higher mortality
Deep location Linked to more regrowth
High Ki-67 (over 20%) Linked to higher recurrence risk
Multifocal tumours Linked to recurrence or spread

These factors come from Wang et al. (2021) and Lampros et al. (2025). Tumours in the hypothalamus or other midline areas tend to be harder to treat (Bianchi et al., 2016).

Development and learning

Many children develop normally. Some may have epilepsy, weakness or learning difficulties, depending on the tumour’s location, the pressure it caused and the treatment needed. Early support helps them reach their potential.

9. Follow-up

Period Typical checks
First year after surgery MRI every 3-4 months
Years 2-5 MRI every 6-12 months
Later Less frequent MRI as advised
Development Regular reviews of growth, development and learning
Seizures Neurology follow-up if needed

10. Living with DIG/DIA

  • Keep all MRI and clinic appointments
  • Know the signs of a blocked shunt: vomiting, sleepiness, headache or bulging fontanelle
  • Give anti-seizure medicines as prescribed
  • Use early intervention services such as physiotherapy, occupational therapy and speech therapy
  • Tell nursery or school staff about your child’s condition
  • Look after yourselves as parents, and accept help from family and support services

After brain surgery

Period What to expect
First days Care in a high-dependency or intensive care unit; close monitoring
First 1-2 weeks Return to the ward, feeding and wound checks; first MRI to see how much tumour remains
Weeks to months Recovery of strength; therapy for any weakness
Pathology results Usually available within one to two weeks, with molecular results later

Support for families

Hearing that your baby has a brain tumour is overwhelming. Children’s cancer centres offer specialist nurses, psychologists, social workers and play specialists. Charities for children with brain tumours provide information, financial help and the chance to meet other families.

11. Frequently asked questions

Question Answer
Is it cancer? It is a tumour, but it is low-grade and usually behaves benignly
Why is it so big? A baby’s skull can expand, so the tumour grows large before symptoms appear
Will my baby need chemotherapy? Only if the tumour regrows and cannot be removed
Will radiotherapy be used? Usually not, to protect the developing brain
Can it come back? Sometimes, especially if not fully removed, so scans continue
Did we cause it? No; nothing parents did is known to cause it
How long will follow-up last? Usually many years, with scans becoming less frequent over time
Can my baby have routine vaccinations? Usually yes, though timing may change during chemotherapy; ask your team
Will my child develop normally? Many do; some need extra support

12. Questions to ask your care team

  • Is the tumour a DIG or DIA?
  • Was it completely removed?
  • Does it have a BRAF or other gene change?
  • Will my child need more surgery or chemotherapy?
  • Does my child need a shunt?
  • How often will MRI scans be done?
  • What developmental support is available?

Resources

  1. Bianchi, F. et al. (2016) ‘Supratentorial tumors typical of the infantile age: desmoplastic infantile ganglioglioma (DIG) and astrocytoma (DIA). A review’, Child’s Nervous System, 32(10), pp. 1833-1838.
  2. Imperato, A. et al. (2021) ‘Desmoplastic infantile astrocytoma and ganglioglioma: a series of 12 patients treated at a single institution’, Child’s Nervous System, 37(7), pp. 2187-2195.
  3. Lampros, M. et al. (2025) ‘Desmoplastic infantile ganglioglioma and astrocytoma: a narrative review of the literature’, Child’s Nervous System, 41(1), 324.
  4. Wang, S. et al. (2021) ‘Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytoma: an individual participant data meta-analysis (IPDMA)’, Journal of Neuro-Oncology, 155(2), pp. 155-163.
  5. National Cancer Institute (2026) Childhood Astrocytomas and Other Gliomas Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-astrocytoma-glioma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.